Lartruvo

Active Ingredient(s): Olaratumab
FDA Approved: * October 19, 2016
Pharm Company: * ELI LILLY AND CO
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Lartruvo Overview

Olaratumab (trade name Lartruvo) is a monoclonal antibody developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.[1] It will be removed from the US and the European markets in the first half of 2019 due to insufficient proof of its medical advantage (see below "Medical uses"). Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of acti...

Read more Lartruvo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Olaratumab

Recent Lartruvo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Olaratumab
  • Injection: 500mg/50ml, 500mg/50ml(10mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Lartruvo: (2 results)

Sorted by National Drug Code
  • 0002-7190 Lartruvo 10 mg/ml Intravenous Injection, Solution by Eli Lilly and Company
  • 0002-8926 Lartruvo 10 mg/ml Intravenous Solution by Eli Lilly and Company

Other drugs which contain Olaratumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 12 December 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA